Physiologically-based kinetic (PBK) models for the alkenylbenzene apiol are defined.
Risk assessment for apiol is done by PBK-based read-across from safrole.
Formation of the 1′-sulfoxy metabolite is 3 times lower for apiol than for safrole.
The MOE estimated for apiol indicates a low priority for risk management.
PBK modelling can contribute to the development of alternatives for animal testing.